Figure 2From: Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapyOverall survival after EBRT with additional HDR-BT boost. (p<0.001 comparing PSA progression during initial HT vs. no PSA progression; p=0.005 comparing PSA progression vs. no HT in log-rank test).Back to article page